• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与新冠病毒mRNA疫苗相关的安全性和不良事件;一项系统评价

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.

作者信息

SeyedAlinaghi SeyedAhmad, Karimi Amirali, Pashaei Zahra, Afzalian Arian, Mirzapour Pegah, Ghorbanzadeh Kobra, Ghasemzadeh Afsaneh, Dashti Mohsen, Nazarian Newsha, Vahedi Farzin, Tantuoyir Marcarious M, Shamsabadi Ahmadreza, Dadras Omid, Mehraeen Esmaeil

机构信息

Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Arch Acad Emerg Med. 2022 May 22;10(1):e41. doi: 10.22037/aaem.v10i1.1597. eCollection 2022.

DOI:10.22037/aaem.v10i1.1597
PMID:35765616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9206826/
Abstract

INTRODUCTION

Knowledge of vaccine-related adverse events is crucial as they are among the most ‎important factors ‎that cause hesitation in receiving vaccines. Therefore, we aimed to systematically ‎review the adverse events ‎related to the mRNA vaccines reported in the literature.‎.

METHOD

A systematic literature search was carried out in the databases of Scopus, PubMed, ‎Cochrane, and Web ‎of Science. We selected original studies that explored the side effects of ‎mRNA ‎COVID-19 vaccines using a two-phase (title/abstract and full-text) screening process.‎.

RESULTS

Cardiac ‎complications were the most commonly reported severe adverse events. It appeared that ‎systemic adverse reactions are more ‎common after the second dose of vaccines. The number of ‎adverse effects reported after the Pfizer vaccine was ‎higher than other vaccines, mostly due to its ‎earlier approval and more widespread use throughout the world. Cardiac adverse events had a ‎‎higher prevalence but no significant association has been found between COVID-19 mRNA vaccines ‎and cardiac ‎adverse events except for myopericarditis. ‎.

CONCLUSION

Vaccines ‎play a crucial role in controlling the COVID-19 pandemic and decreasing ‎mortalities and the results of the present ‎review acknowledge the fact that the benefits outweigh the ‎adverse events of these vaccines.‎.

摘要

引言

了解疫苗相关不良事件至关重要,因为它们是导致人们对接种疫苗犹豫不决的最重要因素之一。因此,我们旨在系统回顾文献中报道的与mRNA疫苗相关的不良事件。

方法

在Scopus、PubMed、Cochrane和科学网数据库中进行了系统的文献检索。我们通过两阶段(标题/摘要和全文)筛选过程,选择了探索mRNA新冠疫苗副作用的原始研究。

结果

心脏并发症是最常报告的严重不良事件。似乎全身不良反应在第二剂疫苗接种后更为常见。辉瑞疫苗接种后报告的不良反应数量高于其他疫苗,这主要是由于其获批时间较早且在全球范围内使用更为广泛。心脏不良事件的发生率较高,但除了心肌心包炎外,未发现新冠mRNA疫苗与心脏不良事件之间存在显著关联。

结论

疫苗在控制新冠疫情和降低死亡率方面发挥着关键作用,本综述结果认可了这些疫苗的益处大于不良事件这一事实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a2d/9206826/9deecd8dd5f7/aaem-10-e41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a2d/9206826/9deecd8dd5f7/aaem-10-e41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a2d/9206826/9deecd8dd5f7/aaem-10-e41-g001.jpg

相似文献

1
Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.与新冠病毒mRNA疫苗相关的安全性和不良事件;一项系统评价
Arch Acad Emerg Med. 2022 May 22;10(1):e41. doi: 10.22037/aaem.v10i1.1597. eCollection 2022.
2
Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review.与灭活新冠疫苗和诺瓦瓦克斯疫苗相关的安全性和不良事件;一项系统评价
Arch Acad Emerg Med. 2022 Jul 7;10(1):e54. doi: 10.22037/aaem.v10i1.1585. eCollection 2022.
3
Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.mRNA COVID-19 疫苗接种后的心脏并发症:病例报告和病例系列的系统评价。
Rev Med Virol. 2022 Jul;32(4):e2318. doi: 10.1002/rmv.2318. Epub 2021 Dec 17.
4
Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.探讨牛津-阿斯利康、辉瑞-BioNTech、莫德纳和强生 COVID-19 疫苗接种对吉兰-巴雷综合征的不良事件。
Sci Rep. 2024 Aug 13;14(1):18767. doi: 10.1038/s41598-024-66999-7.
5
COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis.COVID-19 疫苗相关血栓:系统评价和探索性分析。
Front Immunol. 2021 Nov 29;12:729251. doi: 10.3389/fimmu.2021.729251. eCollection 2021.
6
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
7
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗(ARCT-154)与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性:一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
8
The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review.免疫抑制人群中新冠病毒疫苗加强针的免疫效果和不良事件:一项系统综述
Prev Med Rep. 2024 May 31;44:102778. doi: 10.1016/j.pmedr.2024.102778. eCollection 2024 Aug.
9
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen(强生)和 mRNA COVID-19 疫苗(辉瑞-生物科技和莫德纳)成年受种者发生不良事件后使用 COVID-19 疫苗:免疫实践咨询委员会的更新-美国,2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
10
mRNA Covid-19 vaccines in pregnancy: A systematic review.mRNA 新冠疫苗在妊娠期的应用:一项系统评价。
PLoS One. 2022 Feb 2;17(2):e0261350. doi: 10.1371/journal.pone.0261350. eCollection 2022.

引用本文的文献

1
The Association of SARS-CoV-2 Infection and COVID-19 Vaccination With Sudden Death: An Explorative Review.严重急性呼吸综合征冠状病毒2感染及2019冠状病毒病疫苗接种与猝死的关联:一项探索性综述
Cureus. 2025 Aug 7;17(8):e89527. doi: 10.7759/cureus.89527. eCollection 2025 Aug.
2
Decrypting the Immune Symphony for RNA Vaccines.解读RNA疫苗的免疫乐章
Vaccines (Basel). 2025 Aug 20;13(8):882. doi: 10.3390/vaccines13080882.
3
Immune and hematologicak responses to the third dose of an mRNA COVID-19 vaccine: a six-month longitudinal study.

本文引用的文献

1
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.描述 8 个国家/地区新冠病毒疫苗特殊关注不良事件的背景发生率:跨国网络队列研究。
BMJ. 2021 Jun 14;373:n1435. doi: 10.1136/bmj.n1435.
2
Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.医护人员前瞻性研究中BNT162b2 mRNA新冠疫苗的不良反应及抗体滴度
Open Forum Infect Dis. 2021 Nov 20;9(1):ofab575. doi: 10.1093/ofid/ofab575. eCollection 2022 Jan.
3
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
对第三剂mRNA新冠疫苗的免疫和血液学反应:一项为期六个月的纵向研究。
Front Cell Infect Microbiol. 2025 Jul 10;15:1615227. doi: 10.3389/fcimb.2025.1615227. eCollection 2025.
4
The advent of clinical self-amplifying RNA vaccines.临床自扩增RNA疫苗的出现。
Mol Ther. 2025 Apr 3. doi: 10.1016/j.ymthe.2025.03.060.
5
Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review.与新冠病毒载体疫苗相关的安全性和不良反应:一项系统评价
Tanaffos. 2024 Feb;23(2):102-114.
6
Pathophysiology of oral lesions subsequent to SARS-CoV-2 vaccination: A systematic review.新型冠状病毒2型疫苗接种后口腔病变的病理生理学:一项系统评价。
J Oral Maxillofac Pathol. 2024 Jul-Sep;28(3):443-454. doi: 10.4103/jomfp.jomfp_511_23. Epub 2024 Oct 15.
7
Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice.呈现β峰的新型冠状病毒2型病毒样颗粒疫苗可对小鼠体内的其他变异株提供广泛保护。
Vaccines (Basel). 2024 Sep 2;12(9):1007. doi: 10.3390/vaccines12091007.
8
Psychiatric adverse events associated with the COVID-19 vaccines approved in the Republic of Korea: a systematic review.韩国批准的COVID-19疫苗相关的精神科不良事件:一项系统综述。
Osong Public Health Res Perspect. 2024 Apr;15(2):107-114. doi: 10.24171/j.phrp.2023.0325. Epub 2024 Mar 28.
9
Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence.奥密克戎和德尔塔变异株的比较:当前证据的系统评价。
Infect Disord Drug Targets. 2024;24(7):e050324227686. doi: 10.2174/0118715265279242240216114548.
10
Safety and efficiency of COVID-19 vaccine in North Africa.北非地区 COVID-19 疫苗的安全性和有效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2306703. doi: 10.1080/21645515.2024.2306703. Epub 2024 Feb 2.
BNT162b2 疫苗接种者中和/SARS-CoV-2-S1 结合抗体反应与不良反应和免疫动力学的相关性。
Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y.
4
Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre.与新冠病毒mRNA疫苗接种相关的心肌炎和心包炎:来自地区药物警戒中心的病例
Glob Cardiol Sci Pract. 2021 Oct 30;2021(3):e202118. doi: 10.21542/gcsp.2021.18.
5
Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants.对 COVID-19 疫苗在孕妇、哺乳期妇女及其婴儿中的安全性、免疫原性和有效性的系统评价。
Int J Gynaecol Obstet. 2022 Mar;156(3):406-417. doi: 10.1002/ijgo.14008. Epub 2021 Nov 13.
6
Spectrum of neurological complications following COVID-19 vaccination.接种 COVID-19 疫苗后的神经系统并发症谱。
Neurol Sci. 2022 Jan;43(1):3-40. doi: 10.1007/s10072-021-05662-9. Epub 2021 Oct 31.
7
Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review.新冠疫苗在儿童和青少年中的安全性、免疫原性及有效性:一项系统评价
Vaccines (Basel). 2021 Sep 29;9(10):1102. doi: 10.3390/vaccines9101102.
8
Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis.新型冠状病毒2型疫苗的过敏反应和非过敏反应:一项系统评价与荟萃分析
Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109. doi: 10.1186/s13223-021-00613-7.
9
COVID-19 vaccination in pregnant and lactating women: a systematic review.COVID-19 疫苗在孕妇和哺乳期妇女中的接种:系统评价。
Expert Rev Vaccines. 2021 Dec;20(12):1619-1628. doi: 10.1080/14760584.2021.1986390. Epub 2021 Oct 11.
10
Acute myocardial infarction and myocarditis following COVID-19 vaccination.接种新冠疫苗后出现急性心肌梗死和心肌炎。
QJM. 2023 Apr 29;116(4):279-283. doi: 10.1093/qjmed/hcab252.